Extended Data Fig. 4. In vivo efficacy of AUTO3 in Nalm6 NSG models.

In vivo efficacy of AUTO3 in Nalm6 NSG models. (a-c) CD19+ CD22+ Nalm6 cells transduced to express luciferase were IV administered into NSG mice. After 4 days, 1×10⁶, 3×10⁶ or 5×10⁶ transduced AUTO3 CAR T cells or matched number of non-transduced (NT) T cells were administered IV. a) Bioluminescent imaging (BLI) of the Nalm6 tumor burden measured post CAR T-cell injection. b) The mean total flux radiance quantified pre (day -1) and post administration of 1×10⁶ and 3×10⁶ CAR T-cells (n = 5 for FMC63 and AUTO3, n = 3 for NT). c) BLI of a CD19 knockout (CD19KO) Nalm6 NSG model. NSG mice were IV injected with luciferase positive CD19KO Nalm6 cells 8 days prior to the IV administration of 5×10⁶ transduced CAR T-cells or matched number of non-transduced (NT) T cells (n = 5 biologically independent animals). Statistical analysis performed by two-way ANOVA with Bonferroni correction between FCM63 and AUTO3 over all time points. 1×10⁶ dose **** P = 0.00002. 3×10⁶ dose day 13 ****P < 0.00001, day 16 *** P = 0.00057.